The Expression of hsa-miR-155-5p in Plasma Samples Of Breast Cancer Before And After Chemotherapy
https://doi.org/10.19106/JMedScieSup0048042016018
Meutia Srikandi Fitria
(1*) , Sofia Mubarika Haryana
(2) , Sumadi Lukman Anwar
(3) , Teguh Aryandono
(4) , Dewi Sahfitri Tanjung
(5) , Aprilia Indra Kartika
(6) , Risky Oktriani
(7) , . Irianianiwati
(8) , Dwi Nur Indah Sari
(9)
(1) Graduate Program in Biotechnology, School of Postgraduate, Universitas Gadjah Mada, Yogyakarta,
(2) Doctoral Program, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta,
(3) Dr. Sardjito General Hospital, Yogyakarta, Indonesia,
(4) Doctoral Program, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta,
(5) Graduate Program in Biotechnology, School of Postgraduate, Universitas Gadjah Mada, Yogyakarta,
(6) Graduate Program in Biotechnology, School of Postgraduate, Universitas Gadjah Mada, Yogyakarta,
(7) Department of Biochemistry, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta,
(8) Department of Patology Anatomi, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta,
(9) Graduate Program in Biomedicine, Faculty of Medicine, Universitas Gadjah Mada
(*) Corresponding Author
Abstract
Breast cancer has emerged as the most common cancer-related mortality among women worldwide. Therefore, early cancer detection using biomarkers such as microRNA is needed. One of microRNAs that has an important role in breast cancer development is miR-155. Hsa-miR-155-5p is an oncomir that is commonly dysregulated in breast cancer. This study aims to determine the expression of hsa-miR-155-5p in breast cancer patient’s plasma before and after chemotherapy. We collected 64 samples from breast cancer patients admitted to Dr. Sardjito Hospital in Yogyakarta. RNA from plasma was extracted using RNA Isolation Kit miRCURY-Biofluid. cDNA synthesis was performed using cDNA Synthesis kit II and quantification of miR-155-5p using ExiLent SYBR Green master mix (Exiqon). qRT-PCR results were then analyzed with Livak's method and compared (before and after chemotherapy) with t-test. Expression of miR-155-5p in the breast cancer patients’ plasma after chemotherapy was significantly increased (10.59 times) when compared to before chemotherapy (p = 0.001). We concluded that there was upregulated expression of miR-155-5p after chemotherapy than before chemotherapy. There has not been a known, relevant pathway between hsa-miR-155-5p and chemotherapy regimens nor resistance to chemotherapy.
Keywords: Breast cancer, plasma, hsa-miR-155-5p, oncomiR, chemotherapy.
DOI:
https://doi.org/10.19106/JMedScieSup0048042016018
Article Metrics
Abstract views : 1147
|
views : 1507
Copyright (c) 2017 Meutia Srikandi Fitria, Sofia Mubarika Haryana, Sumadi Lukman Anwar, Teguh Aryandono, Dewi Sahfitri Tanjung, Aprilia Indra Kartika, Risky Oktriani, . Irianianiwati, Dwi Nur Indah Sari
This work is licensed under a
Creative Commons Attribution-NonCommercial 4.0 International License .
<div class="statcounter"><a title="real time web analytics" href="https://statcounter.com/" target="_blank"><img class="statcounter" src="https://c.statcounter.com/10697571/0/23d82b78/0/" alt="real time web analytics"></a></div> <div class="statcounter"><a title="shopify visitor statistics" href="http://statcounter.com/shopify/" target="_blank"><img class="statcounter" src="http://c.statcounter.com/10697571/0/23d82b78/0/" alt="shopify visitor statistics"></a></div>
View My Stats
Journal of the Medical Sciences (Berkala Ilmu Kedokteran ) by Universitas Gadjah Mada is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License . Based on a work at http://jurnal.ugm.ac.id/bik/ .